Effects of pentoxifylline on inflammatorymarkers and blood pressure: A systematic reviewandmeta-analysis of randomized controlled trials

D. Brie, Amirhossein Sahebkar, P.E. Penson, M. Dinca, S. Ursoniu, M.C. Serban, A. Zanchetti, G. Howard, A. Ahmed, W.S. Aronow, P. Muntner, G.Y.H. Lip, N.D. Wong, J. Rysz, M. Banach

    Research output: Contribution to journalArticle

    17 Citations (Scopus)

    Abstract

    Copyright © 2016 Wolters Kluwer Health, Inc.Introduction: Pentoxifylline is a xanthine derivative with potential cardiovascular benefits. Aim: To evaluate the impact of pentoxifylline on blood pressure (BP) and plasma TNF-α, C-reactive protein (CRP) and IL-6 through a systematic review and meta-analysis of randomized controlled trials. Methods: The protocol was registered (PROSPERO: CRD42016035988). The search included PUBMED, ProQuest, Scopus and EMBASE until 1 September 2015 to identify trials reporting BP or inflammatory markers during pentoxifylline therapy. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WDF) and 95% confidence intervals (CIs) as summary statistics. Results: Fifteen studies (16 treatment arms) were found to be eligible for inclusion. Meta-analysis did not suggest any effect of pentoxifylline on either SBP or DBP. Pentoxifylline treatment was associated with a significant reduction in plasma concentrations of TNF-α (WDF: -1.03 pg/ml, 95% CI: -1.54, -0.51; P
    Original languageEnglish
    Pages (from-to)2318-2329
    Number of pages12
    JournalJournal of Hypertension
    Volume34
    Issue number12
    DOIs
    Publication statusPublished - 2016

    Fingerprint

    Dive into the research topics of 'Effects of pentoxifylline on inflammatorymarkers and blood pressure: A systematic reviewandmeta-analysis of randomized controlled trials'. Together they form a unique fingerprint.

    Cite this